Carboxy Methyl Lysine Antikörper
Kurzübersicht für Carboxy Methyl Lysine Antikörper (ABIN1105660)
Target
Alle Carboxy Methyl Lysine (CML) Antikörper anzeigenWirt
Klonalität
Konjugat
Applikation
Klon
-
-
Kreuzreaktivität (Details)
- Species reactivity (tested):Human, Multispecies cross reactant.
-
Aufreinigung
- Protein G Chromatography
-
Immunogen
- Carboxy Methyl Lysine (CML)-KLH
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 0.1 mg/mL
-
Buffer
- PBS, 0.02 % Sodium Azide, 0.1 % BSA
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- Store undiluted at 2-8 °C.
-
-
- Carboxy Methyl Lysine (CML)
-
Andere Bezeichnung
- Carboxy Methyl Lysine
-
Substanzklasse
- Amino Acid
-
Hintergrund
- CML is known to be formed from the oxidation of both carbohydrates and lipids. This makes CML a biomarker of general oxidative stress. Carboxymethyl-lysine (CML) is a well-characterized glycoxidation product that accumulates in tissues with age, and its rate of accumulation is accelerated in diabetes. Glycoxidation products are a subset of advanced glycation endproducts (AGEs) that are formed by the nonenzymatic glycation and subsequent irreversible oxidation of proteins. Oxidative stress and protein modification have been implicated in the pathogenesis of the chronic complications of diabetes, including nephropathy and atherosclerosis. The accumulation of CML in long-lived tissue such as skin collagen reflects oxidative stress over an extended period of the life-span, and has been shown to be greater in patients with diabetic complications than those without complications.Synonyms: CML, Carboxymethyl-lysine
Target
-